stockrowAvantor, Inc.
AVTR Healthcare Medical Instruments & Supplies
Avantor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.6 billion, down 3.41% from fiscal 2024.
- Revenue
- +4.59%
- EPS
- +128.9%
- Free cash flow
- −9.03%
- Total debt
- −4.51%
Quarter to September 2026, against a year earlier
Follow AVTR
Alert me
Avantor, Inc. (AVTR) EBITDA
Avantor, Inc.'s EBITDA for fiscal 2025 was $172.5M, down 88.5% from $1.5B in fiscal 2024. Over the twelve months to 30 September 2026 it was $913.6M. Over the past ten years it has ranged from −$99.5M (fiscal 2017) to $1.6B (fiscal 2022); the current reading is higher than 30% of that period. Avantor, Inc. ranks 10th of 47 Medical Instruments & Supplies companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $172.5M | (88.51%) |
| FY2024 | $1.5B | 35.06% |
| FY2023 | $1.1B | (28.34%) |
| FY2022 | $1.6B | 13.43% |
| FY2021 | $1.4B | 21.51% |
| FY2020 | $1.1B | 14.37% |
| FY2019 | $984.2M | 14.51% |
| FY2018 | $859.5M | — |
| FY2017 | −$99.5M | — |
| FY2016 | $98.0M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $246.6M | 7.64% |
| Jun 2026 | $229.1M | 11.05% |
| Mar 2026 | $206.3M | (10.92%) |
| Dec 2025 | $231.6M | — |
| 29 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| SOLV Solventum Corporation compare | $2.6B |
| BAX Baxter International Inc. compare | $1.5B |
| COO The Cooper Companies, Inc. compare | $928.2M |
| AVTR Avantor, Inc. | $913.6M |
| ALGN Align Technology, Inc. compare | $802.0M |
| BLCO Bausch + Lomb Corporation compare | $801.0M |
| ATR AptarGroup, Inc. compare | $783.0M |
| TFX Teleflex Incorporated compare | $256.2M |
| RGEN Repligen Corporation compare | $155.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on AVTR
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement